Challenges associated with deal-making
Effective deal-making with the right partners is the lifeblood of the pharma industry, crucial for overall success in growing your company and getting your products to market. However, many companies struggle to identify the optimal time to enter or withdraw from a partnership.
Additionally, accurately evaluating a drug under development can be risky due to challenges such as deal complexity, limited resources and manual processes involved in optimizing an agreement1. These obstacles are often compounded by long cycle times, drug project costs and high-risk associated with early-stage assets2.
Early-stage partnering, without sufficient data or due diligence, can quickly result in an incorrect deal evaluation. Early innovators risk under-valuating their asset, and often find themselves having to constantly prove their worth and claims of success probability. Additionally, high demand and expectations of the partner often deters sellers from their goal of meeting targets and milestones.
In our experience, buy-sides often have a strong preference for assets developed in- house. The prospect of spending the time and resources to evaluate a deal, review the evidence, stay up-to-date on global markets and strategize can sometimes create biases against in licensing, potentially delaying deal-making and occasionally killing the deal.
Download the e-Book to reveal:
- Challenges associated with deal-making
- Calculated benefits of in-licensing drug assets
- Predict deal value and clinical success with statistical model
- Data validation of deals analytics algorithm
- Benefits of a data-driven approach for optimal deal evaluation
- Data Sources and Contributors
Sponsored By
Please fill out the form to access the content
